Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? (Q35650444)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

review article

1 reference

title

Prognosis in childhood and adult acute lymphoblastic leukaemia: a question of maturation? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

author name string

Sabine L A Plasschaert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Willem A Kamps

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Edo Vellenga

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

Eveline S J M de Bont

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

publication date

1 February 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

published in

Cancer Treatment Reviews

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

page(s)

37-51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia

18 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Recent approaches in acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Stem cell origins of leukaemia and curability

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Differentiation-linked leukemogenesis in lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Two genetic hits (more or less) to cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Molecular genetics, natural history and the demise of childhood leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Chromosome translocations and covert leukemic clones are generated during normal fetal development

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Molecular tracking of leukemogenesis in a triplet pregnancy.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Prenatal origin of acute lymphoblastic leukaemia in children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Genetic susceptibility to childhood common acute lymphoblastic leukaemia is associated with polymorphic peptide-binding pocket profiles in HLA-DPB1*0201

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Investigation of clonal involvement of myeloid cells in Philadelphia-positive and high hyperdiploid acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Telomeres and telomerase in normal and malignant haematopoietic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Telomeres and telomerase in hematologic neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Sex ratios and the risks of haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Testicular irradiation in childhood lymphoblastic leukaemia. Medical Research Council Working Party on Leukemia in Childhoods

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Is there a gender difference in red blood cell thiopurine methyltransferase activity in healthy children?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Importance of 6-mercaptopurine dose in lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The GIMEMA ALL 0183 trial: analysis of 10-year follow-up. GIMEMA Cooperative Group, Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Intensification of treatment for adults with acute lymphoblastic leukaemia: results of U.K. Medical Research Council randomized trial UKALL XA. Medical Research Council Working Party on Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

1 reference

7 January 2021

Cytogenetic pattern in leukemic cells of patients with constitutional chromosome anomalies

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

DNA double strand breaks (DSB) and non-homologous end joining (NHEJ) pathways in human leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Recent approaches in acute lymphoblastic leukemia in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Childhood acute lymphoblastic leukaemia--current status and future perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Initial features and prognosis in 363 children with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Results of Medical Research Council trial UKALL IX in acute lymphoblastic leukaemia in adults: report from the Medical Research Council Working Party on Adult Leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

[Estimation of tumor cell mass in childhood acute lymphoblastic leukemia: prognostic significance and practical application]

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

[Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81]

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Report and recommendations of the Rome workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Meningeosis leukaemica in adult acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Central nervous system directed therapy in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse--the Children's Cancer Group Experience

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Prognostic importance of morphology (FAB classification) in childhood acute lymphoblastic leukaemia (ALL)

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Cytomorphology of childhood lymphoblastic leukaemia: a prospective study of 2000 patients. United Kingdom Medical Research Council's Working Party on Childhood Leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Reemphasis on lymphoblast L2 morphology as a poor prognostic factor in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Prognostic significance of the revised French-American-British classification for acute lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Myeloid-Antigen Expression in Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Significance of aberrant immunophenotypes in childhood acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Chromosomes and other prognostic factors in acute lymphoblastic leukaemia: a long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Translocations, cancer and the puzzle of specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

In vitro drug resistance profiles of adult acute lymphoblastic leukemia: possible explanation for difference in outcome to similar therapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Corticosteroid resistance is increased in lymphoblasts from adults compared with children: preliminary results of in vitro drug sensitivity study in adults with acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Drug resistance mechanisms in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

MDR1/P-GP expression as a prognostic factor in acute leukemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

High Functional P-glycoprotein Activity is More Often Present in T-cell Acute Lymphoblastic Leukaemic Cells in Adults than in Children

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Messenger RNA analysis of the multidrug resistance related protein (MRP1) and the lung resistance protein (LRP) in de novo and relapsed childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

ABC transporters as phenotypic markers and functional regulators of stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with the prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Progress in the treatment of adolescents with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

Molecular analysis of minimal residual disease in adult acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2803%2900140-3

7 January 2021

10.1016/S0305-7372(03)00140-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14766125%20AND%20SRC:MED&resulttype=core&format=json

18 November 2019

1 reference